Italian multicenter survey to evaluate the opinion of patients and their reference clinicians on the "tolerance" to targeted therapies already available for non-small cell lung cancer treatment in daily clinical practice

Translational Lung Cancer Research

Volumn 3, Issue 3, 2014, Pages 173-180

  Novello, Silvia ^a   Capelletto, Enrica ^a   Cortinovis, Diego ^b   Tiseo, Marcello ^c   Galetta, Domenico ^d   Valmadre, Giuseppe ^e   Casartelli, Clelia ^f   Rapetti, Simonetta Grazia ^a   Rossi, Antonio ^g  

^a UNIVERSITY OF TURIN   (Italy)

^b SAN GERARDO HOSPITAL   (Italy)

^c UNIVERSITY HOSPITAL OF PARMA   (Italy)

^d NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^e Medical Oncology   (Italy)

^f VALDUCE HOSPITAL   (Italy)

^g S G MOSCATI HOSPITAL   (Italy)

Author keywords

Adverse effects; Non small cell lung cancer (NSCLC); Patients' reports; Targeted therapy

Indexed keywords

EID: 84937040104     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2014.06.10     Document Type: Article

References (9)

1. Mok T, Yang JJ, Lam KC. Treating patients with EGFRsensitizing mutations: first line or second line-is there a difference? J Clin Oncol 2013;31:1081-8.
2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123-32.
3. Solomon B, Wilner KD, Shaw AT. Current status of targeted therapy for anaplastic lymphoma kinaserearranged non-small cell lung cancer. Clin Pharmacol Ther 2014;95:15-23.
4. Basch E, Bennett A, Pietanza MC. Use of patientreported outcomes to improve the predictive accuracy of clinician-reported adverse events. J Natl Cancer Inst 2011;103:1808-10.
5. Available online: www.womenagainstlungcancer.eu
6. Available online: http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference:5x7.pdf. Published on 2009, modified in June 2010
7. Dy GK, Adjei AA. Understanding, recognizing, and managing toxicities of targeted anticancer therapies. CA Cancer J Clin 2013;63:249-79.
8. Ricciardi S, Tomao S, de Marinis F. Toxicity of targeted therapy in non-small-cell lung cancer management. Clin Lung Cancer 2009;10:28-35.
9. Quinten C, Maringwa J, Gotay CC, et al. Patient self-reports of symptoms and clinician ratings as predictors of overall cancer survival. J Natl Cancer Inst 2011;103:1851-8.